Clinical outcomes of patients undergoing percutaneous coronary intervention with everolimus-eluting bioabsorbable stent

Abstract

Study design: A descriptive, cross-sectional, retrospective study. Objectives: To identify clinical outcomes and the prevalence of dual antiplatelet therapy (DAPT) 30 days and 12 months after percutaneous coronary intervention (PCI) with an everolimus-eluting bioabsorbable stent (BVS). Methods and casuistry: Data regarding clinical history, procedure, post-procedure outcomes and in-hospital complications, 30-day and one-year follow-up and antiplatelet therapy were collected and analyzed of 169 patients submitted to 182 PCIs with BVS for treatment of 298 lesions. Results: The mean age was 56.9±10.8 years, 84% male. Up to four lesions were treated with PCI, 49% in the anterior descending artery, 81.2% severe (Ellis B2 and C), 99% TIMI 3 postprocedure. After the procedure, non-STEMI was the main in-hospital complication (11.5%). Thirty days after PCI, there were no procedure-related complications and 93.4% were on DAPT. After one year, three patients underwent a new PCI that was not related to the vessel previously treated and 80.2% maintained DAPT. There were no cases of clinically significant stenosis during the follow-up period. Conclusion: The prevalence of DAPT usage was high and there were no early or late complications related to PCI with BVS, confirming the safety and effectiveness of the procedure in the institution.